Phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and AS01B in combination with intravenously administered nivolumab

Jens Tijtgat; Julia Katharina Schwarze; An-Sofie Vander Mijnsbrugge; Steven Raeymaeckers; Ivan Van Riet; Xenia Geeraerts; Latoya Stevens; Sandra Tuyaerts; Bart Neyns

doi:10.1136/jitc-2022-SITC2022.0790

Phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and AS01B in combination with intravenously administered nivolumab

Jens Tijtgat, Julia Katharina Schwarze, An-Sofie Vander Mijnsbrugge, Steven Raeymaeckers, Ivan Van Riet, Xenia Geeraerts, Latoya Stevens, Sandra Tuyaerts, Bart Neyns

Onderzoeksoutput: Meeting abstract (Journal)

1 Downloads (Pure)

Originele taal-2	English
Artikelnummer	790
Pagina's (van-tot)	A823
Tijdschrift	Journal for immunotherapy of cancer
Volume	10
Nummer van het tijdschrift	Suppl 2
DOI's	https://doi.org/10.1136/jitc-2022-SITC2022.0790
Status	Published - 7 nov. 2022
Evenement	SITC Annual Meeting 2022 - Boston Convention Center, Boston, United States Duur: 10 nov. 2022 → 12 nov. 2022

Toegang tot document

10.1136/jitc-2022-SITC2022.0790

2022-PHASE I CLINICAL TRIAL ON INTRATUMORALFinal published version, 196 KB

https://jitc.bmj.com/content/10/Suppl_2/A822

Young Investigator Award
Droogmans, Steven (Recipient), 1 dec. 2006
Prijs: Prize (including medals and awards)

Citeer dit

Tijtgat, J., Schwarze, J. K., Vander Mijnsbrugge, A.-S., Raeymaeckers, S., Van Riet, I., Geeraerts, X., Stevens, L., Tuyaerts, S., & Neyns, B. (2022). Phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and AS01B in combination with intravenously administered nivolumab. Journal for immunotherapy of cancer, 10(Suppl 2), A823. Artikel 790. https://doi.org/10.1136/jitc-2022-SITC2022.0790

Tijtgat, Jens ; Schwarze, Julia Katharina ; Vander Mijnsbrugge, An-Sofie et al. / Phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and AS01B in combination with intravenously administered nivolumab. In: Journal for immunotherapy of cancer. 2022 ; Vol. 10, Nr. Suppl 2. blz. A823.

@article{911d6aa56c374830b3642261eb52264e,

title = "Phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and AS01B in combination with intravenously administered nivolumab",

author = "Jens Tijtgat and Schwarze, {Julia Katharina} and {Vander Mijnsbrugge}, An-Sofie and Steven Raeymaeckers and {Van Riet}, Ivan and Xenia Geeraerts and Latoya Stevens and Sandra Tuyaerts and Bart Neyns",

year = "2022",

month = nov,

day = "7",

doi = "10.1136/jitc-2022-SITC2022.0790",

language = "English",

volume = "10",

pages = "A823",

journal = "Journal for immunotherapy of cancer",

issn = "2051-1426",

publisher = "Springer Verlag",

number = "Suppl 2",

note = "SITC Annual Meeting 2022 ; Conference date: 10-11-2022 Through 12-11-2022",

}

Tijtgat, J, Schwarze, JK , Vander Mijnsbrugge, A-S , Raeymaeckers, S , Van Riet, I , Geeraerts, X , Stevens, L , Tuyaerts, S & Neyns, B 2022, 'Phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and AS01B in combination with intravenously administered nivolumab', Journal for immunotherapy of cancer, vol. 10, nr. Suppl 2, 790, blz. A823. https://doi.org/10.1136/jitc-2022-SITC2022.0790

Phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and AS01B in combination with intravenously administered nivolumab. / Tijtgat, Jens; Schwarze, Julia Katharina ; Vander Mijnsbrugge, An-Sofie et al.
In: Journal for immunotherapy of cancer, Vol. 10, Nr. Suppl 2, 790, 07.11.2022, blz. A823.

Onderzoeksoutput: Meeting abstract (Journal)

TY - JOUR

T1 - Phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and AS01B in combination with intravenously administered nivolumab

AU - Tijtgat, Jens

AU - Schwarze, Julia Katharina

AU - Vander Mijnsbrugge, An-Sofie

AU - Raeymaeckers, Steven

AU - Van Riet, Ivan

AU - Geeraerts, Xenia

AU - Stevens, Latoya

AU - Tuyaerts, Sandra

AU - Neyns, Bart

PY - 2022/11/7

Y1 - 2022/11/7

U2 - 10.1136/jitc-2022-SITC2022.0790

DO - 10.1136/jitc-2022-SITC2022.0790

M3 - Meeting abstract (Journal)

SN - 2051-1426

VL - 10

SP - A823

JO - Journal for immunotherapy of cancer

JF - Journal for immunotherapy of cancer

IS - Suppl 2

M1 - 790

T2 - SITC Annual Meeting 2022

Y2 - 10 November 2022 through 12 November 2022

ER -

Tijtgat J, Schwarze JK , Vander Mijnsbrugge AS , Raeymaeckers S , Van Riet I , Geeraerts X et al. Phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and AS01B in combination with intravenously administered nivolumab. Journal for immunotherapy of cancer. 2022 nov. 7;10(Suppl 2):A823. 790. doi: 10.1136/jitc-2022-SITC2022.0790

Phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and AS01B in combination with intravenously administered nivolumab

Toegang tot document

Prijzen

Young Investigator Award

Citeer dit